000513 Stock Overview
Researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Livzon Pharmaceutical Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.60 |
| 52 Week High | CN¥44.72 |
| 52 Week Low | CN¥32.94 |
| Beta | 0.41 |
| 1 Month Change | -1.45% |
| 3 Month Change | -3.43% |
| 1 Year Change | -8.37% |
| 3 Year Change | -0.55% |
| 5 Year Change | -18.40% |
| Change since IPO | 3,398.50% |
Recent News & Updates
Recent updates
Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings Are Not Doing Enough For Some Investors
Mar 17
Livzon Pharmaceutical Group (SZSE:000513) Has A Rock Solid Balance Sheet
Dec 24We Think You Can Look Beyond Livzon Pharmaceutical Group's (SZSE:000513) Lackluster Earnings
Aug 30Livzon Pharmaceutical Group Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 26A Look At The Fair Value Of Livzon Pharmaceutical Group Inc. (SZSE:000513)
Aug 09Livzon Pharmaceutical Group (SZSE:000513) Is Paying Out Less In Dividends Than Last Year
Jul 02We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right
Jun 07Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Apr 26Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?
Apr 21Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?
Mar 15Shareholder Returns
| 000513 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.4% | 5.2% | 6.4% |
| 1Y | -8.4% | 4.3% | 8.5% |
Return vs Industry: 000513 underperformed the CN Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: 000513 underperformed the CN Market which returned 8.5% over the past year.
Price Volatility
| 000513 volatility | |
|---|---|
| 000513 Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 000513 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000513's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 9,067 | Yanggang Tang | www.livzon.com.cn |
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precocious puberty; and Urofollitropin for injection to treat anovulation and sufferers. It also provides Perospirone hydrochloride tablets to treat schizophrenia; Shenqi Fuzheng Injection to treat weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for treating lung and stomach cancer; anti-viral granules used for clearing heat, eliminating dampness, cooling blood, and detoxifying to treat upper respiratory tract infection and influenza; Tocilizumab injection to treat rheumatoid arthritis; and Recombinant SARSCoV-2 fusion protein vaccine used to prevent diseases caused by SARS-CoV-2 infection.
Livzon Pharmaceutical Group Inc. Fundamentals Summary
| 000513 fundamental statistics | |
|---|---|
| Market cap | CN¥27.92b |
| Earnings (TTM) | CN¥2.06b |
| Revenue (TTM) | CN¥11.81b |
15.0x
P/E Ratio2.6x
P/S RatioIs 000513 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000513 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.81b |
| Cost of Revenue | CN¥4.25b |
| Gross Profit | CN¥7.56b |
| Other Expenses | CN¥5.50b |
| Earnings | CN¥2.06b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 23, 2025
| Earnings per share (EPS) | 2.31 |
| Gross Margin | 64.03% |
| Net Profit Margin | 17.45% |
| Debt/Equity Ratio | 26.5% |
How did 000513 perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield49%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/15 09:19 |
| End of Day Share Price | 2025/04/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Livzon Pharmaceutical Group Inc. is covered by 25 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Helena Qiu | CCB International Securities Limited |
| Shuchang Liu | Changjiang Securities Co. LTD. |